Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Agenus (Details)

v3.24.2.u1
Royalty and Commercial Payment Purchase Agreements - Agenus (Details)
$ in Thousands
 1 Months Ended 6 Months Ended
Sep. 20, 2018
USD ($)
product
Nov. 30, 2020
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs     $ 37,000 $ 14,650  
Short-term royalty and commercial payment receivables     14,257   $ 14,215
Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus          
Agreements          
Amount of milestone payments earned under agreement   $ 10,000      
Agenus | Royalty Purchase Agreement          
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs $ 15,000        
Acquisition of royalty and commercial payment receivables, Long-Term $ 15,000        
Amount of allowance for credit losses     $ 0   $ 0
Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets          
Agreements          
Royalties entity has right to receive (as a percent) 33.00%        
Number of licensed products related to milestone and royalties | product 6        
Milestone payments entity has right to receive (as a percent) 10.00%        
Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product          
Agreements          
Royalties entity has right to receive (as a percent) 33.00%        
Milestone payments entity has right to receive (as a percent) 10.00%        
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones $ 59,500        
Amount of milestone payments earned under agreement   1,000      
Reduction in long-term royalty receivable balance due to receipt of payment   $ 1,000